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Abstract
Systems biology has matured considerably as a discipline over the last decade, yet some of the
key challenges separating current research efforts in systems biology and clinically useful results
are only now becoming apparent. As these gaps are better defined, the new discipline of systems
medicine is emerging as a translational extension of systems biology. How is systems medicine
defined? What are relevant ontologies for systems medicine? What are the key theoretic and
methodologic challenges facing computational disease modeling? How are inaccurate and
incomplete data, and uncertain biologic knowledge best synthesized in useful computational
models? Does network analysis provide clinically useful insight? We discuss the outstanding
difficulties in translating a rapidly growing body of data into knowledge usable at the bedside.
Although core-specific challenges are best met by specialized groups, it appears fundamental that
such efforts should be guided by a roadmap for systems medicine drafted by a coalition of
scientists from the clinical, experimental, computational, and theoretic domains.
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Recent years have seen the rise of systems biology as a
legitimate discipline. Although consensus exists about what
the fundamental tools are (high-throughput data from
several biologic scales, high-definition imaging, and compu-
tational modeling), no such consensus exists as to what
defines the broad agenda of systems biology. A growing
awareness is found that, despite such major technologic
advances, fundamental obstacles separate systems biology
from clinical applications. Bridging these gaps will require a
focused and concerted effort. What defines systems medicine
as a discipline? What should it seek to accomplish? How
should knowledge from disparate sources be assembled into
ontologies relevant to systems medicine? How are multiscale
data to be synthesized by corresponding multiscale models?
What is the burden of proof that such models are valid and
predictive of clinically relevant outcomes? Is network
analysis a useful tool for systems medicine?
Physicians, basic scientists, mathematicians, statisticians
and computer scientists met at the Third Bertinoro Systems
Biology workshop [1], sponsored by the University of
Bologna, focused on the theme ‘Systems Biology Meets the
Clinic’ to address these questions. Participants sought to
identify key challenges facing the successful translation of
systems biology to the clinical arena and discussed and
debated a roadmap seeking to address them. The meeting,
held over a 4-day period, comprised plenary lectures followed
by extensive thematic discussions, formal and informal,
centered on the theme of systems medicine as a distinct
translational discipline [2].
Defining systems medicine
Workshop participants proposed that systems medicine be
defined as the application of systems biology to the
prevention of, understanding and modulation of, and
recovery from developmental disorders and pathologic
processes in human health. Although no clear boundary
exists between systems biology and systems medicine, it
could be stated that systems biology is aimed at a funda-
mental understanding of biologic processes and ultimately at
an exhaustive modeling of biologic networks, whereas
systems medicine emphasizes that the essential purpose and
relevance of models is translational, aimed at diagnostic,
predictive, and therapeutic applications. Accordingly,
advances in systems medicine must be assessed on both a
medical and more basic biologic scale, as the correspon-
dence between medicine and biology is intricate. Some
seemingly straightforward biologic models may have an
important medical impact, although some impressively
complex molecular models may not be immediately
medically relevant. Whereas systems biology may have so far
focused primarily on the molecular scale, systems medicine
must directly incorporate mesoscale clinical information
into its models; in particular, classic clinical variables,
biomarkers, and medical imaging data. As an example, it has
become increasingly clear that prognostic and predictive
models for malignant tumors using expression data cannot
ignore information from classic prognostic indices [3].
Furthermore, because of the necessary multiscale nature of
the models bridging embedded levels of organization from
molecules, organelles, cells, tissues, organs, and all the way
to individuals, environmental factors, populations, and
ecosystems, systems medicine aims to discover and select
the key factors at each level and integrate them into models
of translational relevance, which include measurable
readouts and clinical predictions. Such an approach is
expected to be most valuable when the execution of all experi-
ments necessary to validate sufficiently detailed models is
limited by time, expenses (e.g., in animal models), or basic
ethical considerations (e.g., human experimentation).
Systems medicine as a discipline did not emerge from clinical
medicine, but draws its relevance from it. Conversely,
advances in systems biology created the necessary conditions
and tools for the emergence of systems medicine.
Accordingly, although it may be appropriate to position
systems medicine as an extension of systems biology from a
historical perspective, the former also draws from several
other disciplines, such as clinical medicine and population
epidemiology, less familiar to systems biologists.
Scale-specific modeling versus multiscale modeling
Computational models have for the most part attempted to
assimilate massive data streams collected by using global
measurement technologies (techniques that look at the
complete set of genes, transcripts, proteins, metabolites, or
other features in an organism) by using high-throughput
techniques and have been, by and large, scale specific. Such
attempts target the development of predictive mathematic
and computational models of functional and regulatory
biologic networks. Specific biologic hypotheses can thus be
tested by designing a series of relevant perturbation
experiments [4]. Clear merit inheres in such an incremental
approach, yet its true potential is likely to be realized only
when such data-driven, bottom-up approaches are com-
bined with top-down, model-driven approaches to generate
new medically relevant knowledge.
An open question is whether integrative systems-biology
approaches can reveal underlying principles related to the
aforementioned biologic functions. It is probably improper
to speak of the existence of biologic laws in the sense of
physical laws, yet probably deeper dynamic principles guide
the evolution of biologic systems. Energetic and physical
constraints play an important role in all scale-specific
models. Additional principles at play across multiple scales
in biologic systems are far less apparent. Thus, it appears
prudent at this stage that top-down and multiscale models
seek to recapitulate scale-specific observables. As mentioned
previously, if computational models are to be validated by
experiments such as randomized clinical trials and become
predictive of therapeutic interventions, relevant system
observables must be included.
Ontologies relevant to systems medicine
Considerable attention should be paid to the development of
ontologies relevant to systems medicine. Such ontologies
must reflect knowledge based on biologic function, rather
than on biologic structure. Indeed, structure is permissive to
function, and clearly, a wide variety of structures could have
evolved, under genetic, molecular, or physical constraints to
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accomplish a given function. Examples include energy
generation and storage and transmission of information.
The recent emphasis on mapping structure into function is
vital to the advancement of systems medicine. In addition, it
appears that the development of appropriate ontologies
could promote a (re)interpretation of empiric evidence in
light of such ontologies. As an example, experimental data
often appear to support contradictory hypotheses of limited
scope, when in fact the evidence can be reconciled under a
broader synthesis of the evidence.
Progress in developing meaningful ontologies for systems
medicine will challenge our current intuition of the nature of
a biologic function. Recent efforts at data reduction for
longitudinal expression data, by using principal-component
analysis to identify and monitor health and disease “trajec-
tories”, represent an attempt at understanding such “eigen-
processes” from a data-driven perspective [5,6]. Typically
and unfortunately, such processes have limited intuitive
meaning when interpreted through the prisms of currently
existing ontologies. Alternatively, existing community (for
example, Gene Ontology (GO)) or commercial efforts aimed
at developing a phenotype-driven ontology (e.g., annotating
genes to a priori defined functions such as “cell-cycle” or
“inflammatory response”) are commendable and clearly of
great value, although it is apparent that extensive cross-
contamination exists between such functional assignments
and the response to even the simplest experimental pertur-
bation of functions. Knowledge representations relevant to
systems medicine will probably lie within this spectrum, and
computational efforts will likely be crucial to their
development.
Both data-driven techniques and simulation-based tech-
niques open possibilities of reinterpreting what is meant by
biologic function, yielding new knowledge representations.
Multiscale models that include phenotypes as inputs or
readouts will provide mechanistic insight into the dynamic
interplay of such redefined functions, and plausibly suggest
phenotypically based therapeutic targets.
New knowledge and false discovery
Experimental design and statistical analysis should be dealt
with rigorously, as they play essential roles in discovery and
validation in systems biology and medicine [7]. Study design
is often the weakest point of complex molecular studies in
systems biology and medicine. For example, patients with a
disease such as ovarian cancer may be compared with
normal controls to discern aberrant regulation of pathways.
If controls are not carefully selected to be comparable with
patients demographically and in other covariates (age, sex,
income, social class), then differences observed may be
attributable to factors other than the disease.
Researchers are often unduly optimistic about sample sizes
required to show differences, and they fail to consider many
confounding effects. Interindividual variability in humans
can be large, often the largest effect in a study. This provides
an avenue for exploration of individual effects, leading to
personalized medicine, but also can make detection of
differences across subjects quite difficult.
High-throughput technologies have introduced new
challenges to experimental design and interpretation of
results. Avoiding false positives may result in difficulties in
identifying true positive. Standard approaches to correcting
for multiple-testing on datasets generated by global analysis,
such as expression microarray, rely on the incorrect
assumption that each value is independent of other values.
More recent approaches do not fully resolve this problem
[8]. Greatly increasing sample sizes is generally impractical.
A more practical approach is to make increased use of a
priori biologic knowledge, either by trimming the list of
analytes to a relatively small number for which the multiple-
testing correction is modest, or by testing pathways or
groups of genes [9]. This is usually done not by testing every
group of genes defined by a GO term or a Kyoto Encyclo-
pedia of Genes and Genomes (KEGG) pathway, but by
selectively testing those thought to be of importance.
Because this more-focused approach, in its effort to improve
specificity, is ontology dependent, it may bear a subjective
element as to the certainty of prior knowledge. It, therefore,
also carries the risk of lacking sensitivity.
Addressing the previously mentioned challenges may have
direct clinical implications. A frequent problem encountered
by clinicians is that patients appearing to have the same
disease may not respond to the same treatment. Some
patients even experience severe adverse effects from the
treatment. Variable treatment response is also one of the
most important causes of the huge costs involved in drug
development. Taken together, these cause both increased
suffering and costs. Ideally, physicians should be able,
routinely and noninvasively, to measure a few diagnostic
biomarkers to personalize medication for each patient. At
present, not enough knowledge exists about the causes for
variable treatment responses in most common diseases.
However, recent studies of genetic markers for response to
treatment with anticoagulants indicate that personalized
dosage may become a clinical reality within the next 5 to
10 years [10]. The main problems involved in finding
markers for personalized dosage are that each complex
disease may involve altered interactions between hundreds
or thousands of genes that can differ among patients. This
heterogeneity may, in turn, depend on both genetic and
environmental factors. In addition to this complexity,
significant problems are involved in clinical research.
Ideally, a study aiming to find markers for personalized
medication would involve a known external cause, a key cell
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type, and a read-out, all of which can be studied experi-
mentally in patient samples.
For most complex diseases, all of these factors are not
readily available. It is therefore important to find model
diseases, in which all those factors can be studied together in
patient samples by using high-throughput technologies and
systems biologic principles [11]. Such model diseases might
be used to develop and apply the methods required to find
markers for personalized medicine.
It also has been suggested that the same methods might be
applied to find markers to predict the risk of developing
disease [12]. If successful, this may lead to a new era of
preventive medicine. Finally, the methods may be of great
value for drug development. If it were possible to predict
which patients respond to medication, this would result in
increased efficacy and reduced risk of not being able to market
drugs that have been developed at great cost. Conversely,
delineation of patients that do not respond to a medication
may help to develop new drugs for that specific subgroup. We
suggest that acute inflammatory diseases, such as severe
trauma, sepsis, and pancreatitis, might be very attractive test
beds for the development of such methods. Similarly, chronic
ailments, such as diabetes and other autoimmune disorders,
meet several of the criteria mentioned earlier and are of
prominent clinical and societal relevance.
Network analysis
A network represents a set of objects and their mutual
relations. Much biologic and medical knowledge can be
naturally represented as networks: protein-interaction
networks, metabolic networks, gene co-expression networks,
disease networks, and many more. Growing concerns regard
current trends in network analysis in systems biology and
potential extension to the clinical arena through the
construction of “diseasomes” [13]. Do network representa-
tions actually convey new knowledge, or are they just a
convenient and eye-catching way to represent data? How
can such networks be used to extract new information that is
relevant to understanding biologic systems and guiding
clinical practice? Are current approaches adequately repre-
senting the types of entities and the specific nature of their
relations that determine disease pathophysiologic processes?
What challenges might be resolved and opportunities
opened for both basic research and clinical practice if
standards could be broadly adopted in our knowledge
representation, data collection, publication, and reasoning,
and if fundamental chemical, physical, and biologic entities
and processes could be included in network representations?
How might this be enabled by the adoption of disease-
oriented ontologies? From a mathematic and computational
perspective, what topologic, dynamic, and conditional
properties could allow the identification of the nodes in a
network whose perturbation would yield adversely affected
or clinically improved biologic states?
Although the methods used to analyze networks might still be
primitive, they are already providing useful information,
especially on the genetics of disease. It is now possible to
integrate information from various biologic networks to
identify genes involved in both mendelian and complex
diseases. In such research efforts, careful thought must be
given to how network inferences from microarray and other
types of data are evaluated. The development of such tools
should ideally involve an open dialogue between experi-
mentalists, modelers, and clinicians, who should be able to
assess tools best suited to their application. A need exists for
systematic benchmark testing and comparative evaluation of
the major tools available. For example, current methods tend
to focus more on testing performance capabilities over
simulated data or for functional enrichment in GO categories
that may not be very relevant to clinically relevant phenomena.
The identification of both disease-causative genes and
potential therapeutics has begun to be approached by using
integrative network-relevant methods for knowledge
representation and reasoning [14,15]. Another possibility is
the identification of specific interactions that have been
extensively validated, a so-called ‘gold standard’ for the
identification of causal, mechanistic, and deterministic
factors in a complex network. Some of these issues have
been raised within the Dialogue on Reverse Engineering
Assessment and Methods (DREAM) initiative [16]. For
example, representing gene interactions with graph
algorithms may be a useful method to discover parts of a
network that are not fully resolved [17]. The biologic
plausibility of such representations could then be integrated
with other technologies and discussed with basic biologists
and clinicians. Another approach is to extend network
analysis to evaluate disease-specific ontologies [18].
Conclusions and recommendations
We consider that improvements in academic infrastructure
are sorely needed to facilitate cross-disciplinary trans-
lational studies that can someday connect what can be
learned by using model organisms with real-time samples
from patients. Such improvements include, but are not
limited to sufficient funding, appropriate development of
mechanisms allowing academic recognition of all partici-
pants of transdisciplinary teams, the creation of centers of
excellence in systems medicine and specific training
programs, and enhancement of the attractiveness of a
medical career for individuals with training in quantitative
fields. Recognition of systems medicine in the clinical arena
should be promoted at the professional society and journal
editorial levels. Indeed, whereas bioinformatics exercises
can access mainstream clinical literature on account of the
value of a significance test, the burden of proof appears
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disproportionately higher for computational disease and
therapeutic models of clinical relevance. Additionally, the
construction of a roadmap for systems medicine, facilitated
by enhanced visibility in the more clinically oriented medical
literature, will be essential to chart effort and progress. We
present essential elements of such a roadmap, as well as
underlying rationale (Figure 1).
A serious and useful dialogue between the clinic and systems
biology has begun. We hope that future developments will
provide continuing evidence that the systems-biology
community has taken this development to its heart, building
systems medicine on a millennium of scholarship and
medical tradition.
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